Mizuho maintains Sarepta Therapeutics stock rating, lowers Elevidys sales forecast

Sarepta Therapeutics has completed a significant financial restructuring, refinancing approximately $1.15 billion in 2027 convertible notes to extend maturities and reduce debt, while also generating $174 million from Arrowhead share sales. Despite these moves improving financial flexibility, operational concerns remain as Mizuho significantly cut its Q3 2025 Elevidys sales forecast to $50 million due to shipment disruptions, prompting BofA Securities to lower its price target to $16 with an Underperform rating. This highlights a nuanced outlook where improved balance sheet management contrasts with near-term commercial headwinds.

Analysis

Sarepta Therapeutics has executed a significant financial restructuring to improve its balance sheet, notably refinancing $1.15 billion in convertible senior notes originally due in 2027. This transaction extends the maturity of $605 million to 2030 and reduces overall debt by approximately $123 million, substantially mitigating near-term liquidity concerns surrounding the 2027 obligations. The company further bolstered its cash position by generating at least $174 million in gross proceeds from the sale of over 9.2 million shares in Arrowhead Pharmaceuticals. However, these positive de-risking actions are offset by severe operational headwinds. Mizuho has sharply reduced its Q3 2025 sales forecast for the key drug Elevidys to $50 million, a steep drop from its previous $85 million estimate and far below the $135 million consensus, citing longer-than-expected disruptions from a shipment pause. This commercial uncertainty is reflected in analyst sentiment, with BofA Securities lowering its price target to $16 while maintaining an Underperform rating, and Mizuho holding a Neutral rating with a $19 price target, both below the stock's current trading price of $20.22.

Key Decisions for Investors

• Investors should closely monitor any company communications regarding the resolution of the Elevidys shipment pause, as the drug's sales trajectory is now the primary determinant of near-term stock performance, overshadowing the recent balance sheet improvements.
• The recent debt refinancing provides Sarepta with extended operational runway, but the downward revenue revisions from analysts like Mizuho and the Underperform rating from BofA suggest significant downside risk from the current price level, warranting caution for existing long positions.
• Given the stock's 85% decline over the past year, any consideration of a new position should be weighed against the substantial uncertainty in Elevidys' commercial uptake, with a prudent approach being to await tangible evidence that sales can recover toward consensus estimates.